Navigation Links
Sanofi-aventis Announces Second Quarter 2009 Results
Date:7/29/2009

in the Other Countries region (up 31.8% at euro 85 million). First-half net sales of the product were up 6.9% at euro 1,542 million.

No biosimilar of Lovenox((R)) has been approved in the United States to date.

Taxotere((R)) achieved second-quarter growth of 10.7% to euro 584 million, driven by its use in adjuvant breast cancer treatment and in prostate cancer. Growth was good across all three geographic regions, at 10.7% in Europe (to euro 239 million), 9.6% in the United States (to euro 228 million) and 12.7% in the Other Countries region (to euro 117 million). In Japan, the product continued its advance with net sales up 13.4% at euro 34 million, boosted in particular by the prostate cancer indication approved in the second half of 2008.

In June 2009, the Committee for Medicinal Products for Human Use (CHMP) of the EMEA issued a positive opinion on Roche's Avastin((R)) in combination with Taxotere((R)) as a first line treatment for women with metastatic breast cancer, based on the results of the AVADO study. First-half net sales of Taxotere((R)) were up 9.5% at euro 1,118 million.

Eloxatin((R)), the leading cytotoxic agent in the colorectal cancer market as an adjuvant and as a first-line treatment in the metastatic phase, achieved second-quarter growth of 10.0% in the United States to euro 282 million. Total net sales of the product reflect ongoing competition from generics in Europe, and were down 4.3% at euro 353 million. First-half net sales of Eloxatin((R)) were down 5.7% at euro 697 million. In June 2009, the U.S. District Court for the District of New Jersey ruled against sanofi-aventis by granting summary judgment motions brought by certain generics companies in the U.S. Eloxatin((R)) patent litigation. Sanofi-aventis has appealed this decision, and the Appellate Court issued an order temporarily staying the district court's judgment. As of th
'/>"/>

SOURCE sanofi-aventis
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27

Related biology technology :

1. Sanofi-aventis Announces Settlement of Average Wholesale Price Civil Suits With the U.S. Department of Justice Relating to Anzemet(R)
2. Shareholder Class Action Filed Against Sanofi-Aventis by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
3. Sanofi-aventis SoloSTAR(R) Insulin Pen for Lantus and Apidra Receives the Prestigious GOOD DESIGN Award
4. ThalesNano Inc. and sanofi-aventis R&D Collaborate on Continuous Process Chemistry in Order to Dramatically Reduce Drug Realization Time
5. RainDance Technologies Signs a Collaboration Agreement with sanofi-aventis and Louis Pasteur University to Launch dScreen Consortium within ALSACE BIOVALLEY cluster
6. AEterna Zentaris and Sanofi-Aventis Sign a Development, Commercialization and Licensing Agreement for Cetrorelix in Benign Prostatic Hyperplasia
7. BioWa Announces License of POTELLIGENT(R) Technology to sanofi-aventis
8. Sanofi-aventis U.S. to Acquire Oral Chronic Lymphocytic Leukemia Treatment
9. Sanofi-aventis U.S. Announces Settlement of Medicaid Best Price Investigation
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... University of Leicester has furthered our understanding of ... create new materials using nanosized ,building blocks,. , ... prestigious academic journal Physical Review Letters , ... rich detail the structure and internal atomic motion ... and a single helium atom. , The technique ...
(Date:7/25/2014)... WABC Radio show out of New York ... Young will be hosting California-based Vet-Stem, Inc.’s Founder and CEO, ... in pets. Dr. Harman first visited the show in ... for pets suffering from osteoarthritis and other degenerative diseases, as ... forward. , Young has invited Dr. Harman back to dial ...
(Date:7/25/2014)... 2014  Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD ... development and commercialization of a once-daily, oral therapy for ... announced financial results for the period ended June 30, ... , Reported cash and cash equivalents totaling $37.4 million ... 31, 2013.  , Reported a net loss of ...
(Date:7/25/2014)... Sinovac Biotech Ltd. (Nasdaq: SVA ), ... , today announced that it will release its unaudited ... after market close on Thursday, August 14, 2014 EDT. The ... opening on Friday, August 15, 2014, at 8:00 a.m. EDT ... to review the Company,s financial results and provide an update ...
Breaking Biology Technology:Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster 2Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster 3Robert J. Harman, DVM, Founder and CEO of Vet-Stem, Inc. to Join New York Radio Host Lorry Young in Upcoming Episode of A “Paws” For Your Pet 2Robert J. Harman, DVM, Founder and CEO of Vet-Stem, Inc. to Join New York Radio Host Lorry Young in Upcoming Episode of A “Paws” For Your Pet 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6Sinovac to Host Conference Call to Report Second Quarter 2014 Unaudited Financial Results 2
... , EAST BRUNSWICK, N.J., Sept. 8 Savient ... abstracts relating to KRYSTEXXA(TM) (pegloticase) development and treatment failure gout will ... in Philadelphia from October 16-21, 2009. The posters will be ... and include: , , , ...
... , CAMBRIDGE, Massachusetts, September 8 ... the global specialty biopharmaceutical company, is,committed to doing everything ... imiglucerase supply shortage. Shire is pleased to be,able to ... previously,anticipated commercial launch world wide. , ...
... , SAN DIEGO, Sept. 8 Biomatrica, Inc., the ... key appointments that will expand the breadth of leadership and commercial ... continued rapid growth in the development and commercialization of products for ... , Martin Latterich, Ph.D., has joined the company ...
Cached Biology Technology:Multiple Abstracts Related to KRYSTEXXA(TM) Development and Treatment Failure Gout to be Presented at the 2009 ACR/ARHP Annual Scientific Meeting 2Multiple Abstracts Related to KRYSTEXXA(TM) Development and Treatment Failure Gout to be Presented at the 2009 ACR/ARHP Annual Scientific Meeting 3Multiple Abstracts Related to KRYSTEXXA(TM) Development and Treatment Failure Gout to be Presented at the 2009 ACR/ARHP Annual Scientific Meeting 4Update on velaglucerase alfa 2Update on velaglucerase alfa 3Biomatrica Makes Several Key Appointments as Part of Continued Growth Plan 2Biomatrica Makes Several Key Appointments as Part of Continued Growth Plan 3Biomatrica Makes Several Key Appointments as Part of Continued Growth Plan 4Biomatrica Makes Several Key Appointments as Part of Continued Growth Plan 5
(Date:7/25/2014)... the Terra satellite show the different areas that have been ... The burn scars show up as reddish-brown splotches of ... across the remote parts of Eastern Russia in the Sakha ... instrument, it is still possible to see the smoke ... noted below show the devastating number of fires that have ...
(Date:7/25/2014)... of biomedical engineering at the University of Houston, ... and artificial organ development., "Introduction to Tissue Engineering: ... entering into the field of artificial organ development. ... engineering at UH, served as a series editor ... are other published books on the subject of ...
(Date:7/25/2014)... (DTT), which is derived from diffusion tensor imaging ... tracts, such as the corticospinal tract, the rubrospinal ... corticospinal tract is known to be a major ... brain. Several studies have reported on injury of ... some studies have demonstrated recovery of a corticospinal ...
Breaking Biology News(10 mins):University of Houston researcher publishes textbook on tissue engineering 2
... pressure were recently identified in a comprehensive international ... study, in which Uppsala University researchers participated, are ... Nature Genetics . High blood pressure ... Previous studies have shown that it is extremely ...
... May 8 Military and civilian personnel from the ... local homeland security, law enforcement and other first-responder personnel ... been encouraged to register and attend the 2009 Force ... held at Stafford Regional Airport and Marine Corps Base, ...
... and south sides of a house may decrease summertime ... a recent study* of California homes by researchers from ... the U.S. Department of Agriculture (USDA). The first ... the effects of shade on 460 single-family homes in ...
Cached Biology News:Comprehensive genetic study paves way for new blood-pressure medicines 2Demonstration Features Commercial Technology for Combating Terrorism 2New study: Home energy savings are made in the shade 2
Moue Serum 8-12 Weeks Old...
... is collected off the clot fasted non-Swiss Albino mice ... Available Anticoagulants: N-02: Citrate N-04: ... Potassium Oxalate N-10: EDTA (Na) ... CPD N-09: K3EDTA N-11: ...
Contains 100 positive controls for effective screening of HDAC inhibitors by fluorometric method....
dynactin 4, mRNA (cDNA clone MGC:3248 IMAGE:3505855), complete cds...
Biology Products: